Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07816276
Starting soon Observational

THE EFFECTS OF MULTIPLE DRUG USE ON BALANCE, FALL RISK, AND COGNITIVE STATUS

NCT07816276 · tracked via the Priya Life Science Turkey tracker
Sponsor
Ondokuz Mayıs University
Phase
Observational
Started
2026-09-01
Last updated
2026-09-11

Condition(s) studied

Polypharmacy (Individuals Treated With 4 or More Medications)

Study summary

This study aims to evaluate the effects of polypharmacy on balance, fall risk, cognitive status, vestibular function, and hearing among individuals living in nursing homes. The study investigates the relationship between polypharmacy and balance, fall risk, cognitive, vestibular, and hearing-related outcomes.

Eligibility

Sex
ALL
Min age
60 Years
Max age
99 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Individuals aged 60 years and older * Individuals living in nursing homes in Samsun * Individuals in the polypharmacy group using the defined number of medications and individuals in the control group using fewer or no medications * Ability to walk independently without an assistive device * Ability to communicate verbally * Voluntary participation in the study * No complaint or diagnosis of vestibular disorder * Ability to read and write Exclusion Criteria: * Individuals younger than 60 years * Severe dementia * Use of an assistive walking device * Central nervous system or visual pathologies that may affect balance * Previous diagnosis of vestibular pathology * History of severe neurological diseases such as stroke * Inability to provide reliable responses to the assessments * Inability to cooperate with the assessment procedures * Inability to read and write

Primary outcome measure(s)

  • Standardized Mini-Mental State Examination — Baseline
    Description: Individuals' cognitive status was assessed using the Standardized Mini-Mental State Examination and compared between the polypharmacy group and the control group.
  • Cognitive-Vestibular Function Scale — Baseline
    Individuals' cognitive-vestibular functions were assessed using the Cognitive-Vestibular Function Scale and compared between the polypharmacy group and the control group.

Trial sites (1)

FacilityCityRegionStatus
Ondokuz Mayıs University Samsun Samsun

More Ondokuz Mayıs University trials in Turkey

Mindfulness-Based Psychoeducation for Women With Gynecological Cancer Starting soon
Nutrition Intervention for Women With Polycystic Ovary Syndrome Enrolling by invitation
Body Roundness Index and Mortality in ICU Patients Starting soon
Kinesiophobia, Pain and Disability in Chronic Neck Pain Recruiting
WhatsApp Radio Taiso Exercise Program for Adults Aged 60+ Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07816276 on ClinicalTrials.gov ↗ ← All trials in Turkey